The data consistently showed that chemerin targeted tumor cells and tumor-associated endothelial cells, the major source of GM-CSF and IL-6, via interaction with CMKLR1 and CCRL2, reducing expression of inflammatory cytokines and inhibiting NF-κB activation (82). Here, NFKB1 is linked to neoplasm.